SCHEMBL6345600

SCHEMBL6345600

CCO/N=C(/C)c1c[c]ccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
PTBP1 P26599 1/20 0.38
HPGD P15428 1/20 0.35
PPARA Q07869 6/20 0.35
PPARG P37231 6/20 0.34
DRD4 P21917 1/20 0.33
MAPT P10636 1/20 0.32
ALDH1A1 P00352 1/20 0.32
ADRA1A P35348 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL695964 1.00 LMNA (0.47) LMNAL3MBTL1MAPK1HTTSMN1; SMN2
SCHEMBL695965 1.00 LMNA (0.47) LMNAL3MBTL1MAPK1HTTSMN1; SMN2
SCHEMBL696077 0.81 L3MBTL1 (0.39) LMNAL3MBTL1MAPK1HTTSMN1; SMN2
SCHEMBL696078 0.81 L3MBTL1 (0.39) LMNAL3MBTL1MAPK1HTTSMN1; SMN2
SCHEMBL6970352 0.81 L3MBTL1 (0.39) LMNAL3MBTL1MAPK1HTTSMN1; SMN2
SCHEMBL5222852 0.80 PPARG (0.48) LMNAL3MBTL1MAPK1HTTSMN1; SMN2
SCHEMBL5958327 0.79 LMNA (0.48) LMNAL3MBTL1MAPK1HTTSMN1; SMN2
SCHEMBL5958328 0.79 LMNA (0.48) LMNAL3MBTL1MAPK1HTTSMN1; SMN2
SCHEMBL23635710 0.78 LMNA (0.74) LMNAL3MBTL1MAPK1HTTSMN1; SMN2
SCHEMBL2736632 0.78 LMNA (0.74) LMNAL3MBTL1MAPK1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050101783-A1 N-(heterocycle-methyl)alkylamine derivative, process for producing the same, and bactericide KUREHA CORPORATION (JP) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101783-A1 N-(heterocycle-methyl)alkylamine derivative, process for producing the same, and bactericide HBZ, ACMSD, HDHD5 LMNA 2729/4885L3MBTL1 1563/4885MAPK1 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.